Verrica Pharmaceuticals Reports Record YCANTH Revenue and Secures $15 Million in Funding
Verrica Pharmaceuticals posted record quarterly net product revenue for YCANTH and unlocked $15 million in capital to support upcoming clinical trials.
🏢CompaniesPhoto: Motley Fool
Key points
- Verrica reported record quarterly U.S. net product revenue for YCANTH.
- The company unlocked $15 million in non-dilutive capital to fund operations through 2027.
- Management is advancing Phase III trials for common warts and exploring VP-315 for Gorlin syndrome.
Verrica Pharmaceuticals announced record quarterly U.S. net product revenue for its flagship product, YCANTH, during its third quarter 2026 corporate update. Led by President and CEO Jayson Rieger, the commercial division focused on driving loyalist adoption among prescribers while minimizing prescription leakage and optimizing insurance coverage pathways.
Clinical Progress and New Drug Exploration
In addition to commercial milestones, the company advanced its global Phase III program targeting common warts, which management notes represents a major dermatological market. Verrica confirmed the completion of enrollment for its first pivotal trial and surpassed 50 percent enrollment for the second. Additionally, the firm revealed plans to study VP-315 as a potential treatment for Gorlin syndrome, a rare genetic condition characterized by recurring basal cell carcinomas.
Capital Structure and Liquidity
To support its ongoing research initiatives, Verrica unlocked an additional $15 million in non-dilutive capital after hitting predefined operational benchmarks tied to a credit facility established in August. According to interim CFO John Kirby and the executive team, this funding is projected to finance operations through the anticipated Phase III readouts for the common warts program scheduled for 2027.
What to watch next: Investors should monitor the upcoming Phase III trial data readouts for the common warts program expected in early and mid-2027.
Source Motley Fool — fool.com/earnings/call-transcripts/2026/11/13/verrica-vrca-q3-2026-… ↗
Read next
🧠AI AnalysisCredo Technology Shares Fall Sharply Following September Earnings Report
Credo stock has declined 32% since its September 1 earnings release, trading significantly lower than its June record high.
🧠AI AnalysisArtificial Intelligence Dominates Market Focus Once Again
Market attention remains anchored entirely on the artificial intelligence sector as alternative topics take a back seat for another consecutive week.
🧠AI AnalysisNvidia Shares Slide as CEO Jensen Huang Resigns Following Scandal
Nvidia's market capitalization dropped to $3.93 trillion after co-founder Jensen Huang resigned following revelations of personal misconduct.
🧠AI AnalysisEmbraer Maintains Buy Rating Following Third-Quarter Performance
An independent analyst has reaffirmed a buy rating on Embraer shares following the release of the company's third-quarter financial results.
🧠AI AnalysisAnthropic Targets $1.4 Trillion Valuation in Upcoming Nasdaq Debut
AI developer Anthropic is set to list on the Nasdaq with a price range of $70 to $78 per share, potentially valuing the company at $1.4 trillion.
🧠AI AnalysisLowe's Positioned for Growth Amid Expanding Home Remodeling Budgets
An analysis of Lowe's Companies suggests the home improvement retailer is well-positioned to capitalize on increasing consumer spending in the remodeling sector.